VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Search Videos by Topic or Participant
Browse by Series:

Final Comments From Panelists on Managing CML

Panelists: Jessica K. Altman, MD, Northwestern University; Stuart L. Goldberg, MD, Rutgers;Elias Jabbour, MD, MD Anderson; Neil P. Shah, MD, PhD; UC
Published: Thursday, Jun 11, 2015
For High-Definition, Click
In the final segment of the discussion, panelists share their closing thoughts on the treatment of patients with chronic myeloid leukemia (CML). Neil Pravin Shah, MD, stresses that monitoring patients is essential, whether they are remaining on or discontinuing therapy. In order to achieve optimal outcomes, patients with CML should be referred to a team of oncologists who are seasoned in treating this disease, particularly when a patient is not responding as well as hoped, B. Douglas Smith, MD, suggests.

There are several new therapies available for the treatment of CML, including highly active agents for patient with resistant or intolerant disease, notes Elias Jabbour, MD. These therapies enhave the importance of monitoring response. If one therapy stops working, there are other options. Most patients will do well on modern therapies, Stuart L. Goldberg, MD, adds; however, if outcomes do not seem to match expectations, seeking another interpretation of a test or finding help with a management decision could improve outcomes and result in proper care for patients.
Slider Left
Slider Right
For High-Definition, Click
In the final segment of the discussion, panelists share their closing thoughts on the treatment of patients with chronic myeloid leukemia (CML). Neil Pravin Shah, MD, stresses that monitoring patients is essential, whether they are remaining on or discontinuing therapy. In order to achieve optimal outcomes, patients with CML should be referred to a team of oncologists who are seasoned in treating this disease, particularly when a patient is not responding as well as hoped, B. Douglas Smith, MD, suggests.

There are several new therapies available for the treatment of CML, including highly active agents for patient with resistant or intolerant disease, notes Elias Jabbour, MD. These therapies enhave the importance of monitoring response. If one therapy stops working, there are other options. Most patients will do well on modern therapies, Stuart L. Goldberg, MD, adds; however, if outcomes do not seem to match expectations, seeking another interpretation of a test or finding help with a management decision could improve outcomes and result in proper care for patients.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x